tailieunhanh - báo cáo khoa học: "Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a 24-year clinical experience with 178 patients"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a 24-year clinical experience with 178 patients | Journal of Hematology Oncology BioMed Central Open Access Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome TTP-HUS a 24-year clinical experience with 178 patients Mark Levandovsky1 Danielle Harvey2 Primo Lara3 4 and Ted Wun 3 4 Address 1Division of Hematology-Oncology Weill School of Medicine Cornell University New York NY USA 2Department of Public Health Sciences University of California Davis School of Medicine Sacramento CA USA 3Division of Hematology and Oncology UC Davis School of Medicine Sacramento CA USA and 4VA Northern California Health Care System Sacramento CA USA Email Mark Levandovsky-mlevandovsky1@ Danielle Harvey-djharvey@ Primo Lara - Ted Wun - Corresponding author Published I December 2008 Journal of Hematology Oncology 2008 1 23 doi I756-8722-I-23 Received 26 August 2008 Accepted I December 2008 This article is available from http content I I 23 2008 Levandovsky et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome TTP-HUS are related and uncommon disorders with a high fatality and complication rate if untreated. Plasma exchange therapy has been shown to produce high response rates and improve survival in patients with many forms of TTP-HUS. We performed a retrospective cohort study of 178 consecutively treated patients with TTP-HUS and analyzed whether clinical or laboratory characteristics could predict for important short- and long-term outcome measures. Results Overall 30-day mortality was 16 n 27 . 171 patients 96 received plasma exchange as the principal treatment with a mean of 8 exchanges and a .